SG11202007652UA - Camk2d antisense oligonucleotides and uses thereof - Google Patents
Camk2d antisense oligonucleotides and uses thereofInfo
- Publication number
- SG11202007652UA SG11202007652UA SG11202007652UA SG11202007652UA SG11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA
- Authority
- SG
- Singapore
- Prior art keywords
- camk2d
- antisense oligonucleotides
- antisense
- oligonucleotides
- camk2d antisense
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/32—Devices for opening or enlarging the visual field, e.g. of a tube of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
- A61B17/0206—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors with antagonistic arms as supports for retractor elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00477—Coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/50—Supports for surgical instruments, e.g. articulated arms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633502P | 2018-02-21 | 2018-02-21 | |
US201862635954P | 2018-02-27 | 2018-02-27 | |
US201862665998P | 2018-05-02 | 2018-05-02 | |
US201862778679P | 2018-12-12 | 2018-12-12 | |
PCT/US2019/018947 WO2019165067A1 (en) | 2018-02-21 | 2019-02-21 | Camk2d antisense oligonucleotides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007652UA true SG11202007652UA (en) | 2020-09-29 |
Family
ID=65729436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007652UA SG11202007652UA (en) | 2018-02-21 | 2019-02-21 | Camk2d antisense oligonucleotides and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US11058767B2 (de) |
EP (1) | EP3755800A1 (de) |
JP (1) | JP2021513861A (de) |
KR (1) | KR20200140805A (de) |
CN (1) | CN112020559A (de) |
AU (1) | AU2019226001A1 (de) |
BR (1) | BR112020016347A2 (de) |
CA (1) | CA3091789A1 (de) |
IL (1) | IL276549A (de) |
MX (1) | MX2020008581A (de) |
SG (1) | SG11202007652UA (de) |
WO (1) | WO2019165067A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1814474B1 (de) | 2004-11-24 | 2011-09-14 | Samy Abdou | Vorrichtungen zur platzierung eines orthopädischen intervertebralen implantats |
US8764806B2 (en) | 2009-12-07 | 2014-07-01 | Samy Abdou | Devices and methods for minimally invasive spinal stabilization and instrumentation |
US8845728B1 (en) | 2011-09-23 | 2014-09-30 | Samy Abdou | Spinal fixation devices and methods of use |
US20130226240A1 (en) | 2012-02-22 | 2013-08-29 | Samy Abdou | Spinous process fixation devices and methods of use |
US9198767B2 (en) | 2012-08-28 | 2015-12-01 | Samy Abdou | Devices and methods for spinal stabilization and instrumentation |
US9320617B2 (en) | 2012-10-22 | 2016-04-26 | Cogent Spine, LLC | Devices and methods for spinal stabilization and instrumentation |
US10857003B1 (en) | 2015-10-14 | 2020-12-08 | Samy Abdou | Devices and methods for vertebral stabilization |
US10898175B2 (en) * | 2016-10-04 | 2021-01-26 | Jgmg Bengochea, Llc | Retractor extension clip systems |
US10973648B1 (en) | 2016-10-25 | 2021-04-13 | Samy Abdou | Devices and methods for vertebral bone realignment |
US10744000B1 (en) | 2016-10-25 | 2020-08-18 | Samy Abdou | Devices and methods for vertebral bone realignment |
WO2019165067A1 (en) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
US11806250B2 (en) | 2018-02-22 | 2023-11-07 | Warsaw Orthopedic, Inc. | Expandable spinal implant system and method of using same |
US11179248B2 (en) | 2018-10-02 | 2021-11-23 | Samy Abdou | Devices and methods for spinal implantation |
KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
US11602337B2 (en) | 2019-04-24 | 2023-03-14 | Nuvasive, Inc. | Transmission assembly |
JP7337964B2 (ja) | 2019-06-18 | 2023-09-04 | ニューヴェイジヴ,インコーポレイテッド | 組織牽引システム |
US11547395B2 (en) | 2019-06-18 | 2023-01-10 | Nuvasive, Inc. | Tissue retraction system |
CN110731803B (zh) * | 2019-11-20 | 2021-05-25 | 吕振乾 | 一种心外科手术辅助器 |
WO2021158810A1 (en) | 2020-02-05 | 2021-08-12 | Bristol-Myers Squibb Company | Oligonucleotides for splice modulation of camk2d |
US11224415B1 (en) * | 2020-07-10 | 2022-01-18 | Warsaw Orthopedic, Inc. | Tissue retractor |
US11376134B1 (en) | 2020-11-05 | 2022-07-05 | Warsaw Orthopedic, Inc. | Dual expanding spinal implant, system, and method of use |
US11638653B2 (en) | 2020-11-05 | 2023-05-02 | Warsaw Orthopedic, Inc. | Surgery instruments with a movable handle |
US11395743B1 (en) | 2021-05-04 | 2022-07-26 | Warsaw Orthopedic, Inc. | Externally driven expandable interbody and related methods |
US11291554B1 (en) | 2021-05-03 | 2022-04-05 | Medtronic, Inc. | Unibody dual expanding interbody implant |
US11285014B1 (en) | 2020-11-05 | 2022-03-29 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system, and method |
US11963881B2 (en) | 2020-11-05 | 2024-04-23 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system, and method |
US11564724B2 (en) | 2020-11-05 | 2023-01-31 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system and method |
US11517443B2 (en) | 2020-11-05 | 2022-12-06 | Warsaw Orthopedic, Inc. | Dual wedge expandable implant, system and method of use |
US11833059B2 (en) | 2020-11-05 | 2023-12-05 | Warsaw Orthopedic, Inc. | Expandable inter-body device, expandable plate system, and associated methods |
WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
US11612499B2 (en) | 2021-06-24 | 2023-03-28 | Warsaw Orthopedic, Inc. | Expandable interbody implant |
US11730608B2 (en) | 2021-07-13 | 2023-08-22 | Warsaw Orthopedic, Inc. | Monoblock expandable interbody implant |
WO2023064924A1 (en) | 2021-10-14 | 2023-04-20 | Codiak Biosciences, Inc. | Modified producer cells for extracellular vesicle production |
US11850163B2 (en) | 2022-02-01 | 2023-12-26 | Warsaw Orthopedic, Inc. | Interbody implant with adjusting shims |
WO2023225665A1 (en) | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3749088A (en) | 1971-06-23 | 1973-07-31 | W Kohlmann | Surgical retractor device |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
US6057111A (en) | 1996-11-13 | 2000-05-02 | Quark Biotech, Inc. | Gene identification method |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
DE04020014T1 (de) | 1997-09-12 | 2006-01-26 | Exiqon A/S | Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga |
US6139493A (en) * | 1998-07-08 | 2000-10-31 | Koros; Tibor B. | Retractor with adjustable length blades and light pipe guides |
EP1152009B2 (de) | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Analoga von nukleosiden und oligonukleotiden |
NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
GB2375172A (en) | 2000-02-07 | 2002-11-06 | Quark Biotech Inc | Fas pathway genes |
EP1355578A1 (de) * | 2001-01-29 | 2003-10-29 | Stephen Ritland | Rückziehvorrichtung und verfahren zur platzierung von wirbelsäulenpedikelschrauben |
EP1478772A2 (de) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nukleinsäure- und aminosäuresequenzen im zusammenhang mit schmerzen |
WO2005060667A2 (en) | 2003-12-19 | 2005-07-07 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
US20070072178A1 (en) | 2001-11-05 | 2007-03-29 | Torsten Haferlach | Novel genetic markers for leukemias |
WO2003065006A2 (en) | 2002-01-31 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
US20040101855A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of PPAR binding protein expression |
US9259144B2 (en) | 2002-07-11 | 2016-02-16 | Nuvasive, Inc. | Surgical access system and related methods |
WO2004012817A2 (en) | 2002-07-31 | 2004-02-12 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
JP2006513701A (ja) | 2002-10-11 | 2006-04-27 | アーラム バイオシステムズ インコーポレイテッド | 核酸ベースのシグナルトランスデューサーを含む立体構造的に敏感なプローブを有する標的検出システム |
US7850608B2 (en) | 2002-10-25 | 2010-12-14 | K2M, Inc. | Minimal incision maximal access MIS spine instrumentation and method |
EP2141233B1 (de) | 2002-11-18 | 2016-10-19 | Roche Innovation Center Copenhagen A/S | Antisense-Entwurf |
US7691057B2 (en) | 2003-01-16 | 2010-04-06 | Nuvasive, Inc. | Surgical access system and related methods |
US7256200B2 (en) | 2003-02-10 | 2007-08-14 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Method and composition for potentiating an oplate analgesic |
US7819801B2 (en) | 2003-02-27 | 2010-10-26 | Nuvasive, Inc. | Surgical access system and related methods |
US20050085436A1 (en) | 2003-07-08 | 2005-04-21 | Hao Li | Method to treat conditions associated with insulin signalling dysregulation |
US7481766B2 (en) | 2003-08-14 | 2009-01-27 | Synthes (U.S.A.) | Multiple-blade retractor |
US20050137461A1 (en) * | 2003-12-18 | 2005-06-23 | Depuy Spine, Inc. | Telescoping blade assembly and instruments for adjusting an adjustable blade |
US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
WO2006042241A2 (en) | 2004-10-08 | 2006-04-20 | Nuvasive, Inc. | Surgical access system and related methods |
JP2006223228A (ja) | 2005-02-18 | 2006-08-31 | Dainippon Sumitomo Pharma Co Ltd | 自己免疫疾患治療剤のスクリーニング方法 |
US20060287584A1 (en) * | 2005-06-16 | 2006-12-21 | Javier Garcia-Bengochia | Surgical retractor extensions |
CN1904900A (zh) * | 2005-07-28 | 2007-01-31 | 中国科学院生物物理研究所 | 人类的内源性siRNA序列及其应用和筛选方法 |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
EP1962888A2 (de) * | 2005-11-18 | 2008-09-03 | Myogen, Inc. | Verwendung von camkii und hdacs bei der behandlung von herzkrankheiten |
KR20130042043A (ko) | 2006-01-27 | 2013-04-25 | 아이시스 파마수티컬즈 인코포레이티드 | 6-변형된 바이시클릭 핵산 유사체 |
CA2644162A1 (en) * | 2006-03-07 | 2007-09-13 | Telethon Institute For Child Health Research | Method for diagnosing and/or predicting the development of an allergic disorder and agents for treating and/or preventing same |
JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ, インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
WO2007134181A2 (en) | 2006-05-11 | 2007-11-22 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2008020435A2 (en) | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions and methods for treatment of mood disorders |
ES2534430T3 (es) | 2006-08-28 | 2015-04-22 | The University Of Western Australia | Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN |
GB0617222D0 (en) | 2006-08-31 | 2006-10-11 | Vereniging Het Nl Kanker I | Antibiotics |
US8062217B2 (en) * | 2007-01-26 | 2011-11-22 | Theken Spine, Llc | Surgical retractor with removable blades and method of use |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
WO2008152636A2 (en) * | 2007-06-15 | 2008-12-18 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting nadph oxidase expression |
AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
DE202007012284U1 (de) | 2007-09-01 | 2007-10-25 | Aesculap Ag & Co. Kg | Chirurgischer Retraktor |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
US8841423B2 (en) | 2008-04-28 | 2014-09-23 | University Of Iowa Research Foundation | Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
EP2177615A1 (de) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren für eine Genom-weite Erkennung für den Ausdruck regelmäßiger Sequenzen und Verwendung von daraus abgeleiteten Genen und Molekülen für die Diagnose und Therapie von Stoffwechsel- und/oder Tumorerkrankungen |
US8226554B2 (en) | 2008-10-30 | 2012-07-24 | Warsaw Orthopedic, Inc. | Retractor assemblies for surgery in a patient |
WO2010120969A1 (en) | 2009-04-15 | 2010-10-21 | Board Of Regents, The University Of Texas System | Targeting of the mir-30 family and let-7 family as a treatment for heart disease |
ES2555057T3 (es) * | 2009-06-12 | 2015-12-28 | Roche Innovation Center Copenhagen A/S | Nuevos potentes compuestos antisentido anti-ApoB |
US8563528B2 (en) * | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
EP2462153B1 (de) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclische cyclohexosenukleinsäureanaloga |
WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
US9737288B2 (en) * | 2010-03-11 | 2017-08-22 | Globus Medical, Inc | Tissue retractor and methods of use |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2606130B1 (de) | 2010-08-16 | 2019-03-13 | Duke University | Camkk-beta als marker bei prostatakrebs |
WO2013023084A2 (en) | 2011-08-09 | 2013-02-14 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
EP2751270B1 (de) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-konjugat-komplexe und ihre verwendung |
US9603949B2 (en) * | 2011-09-01 | 2017-03-28 | University Of Iowa Research Foundation | Oligonucleotide-based probes for detection of bacterial nucleases |
AU2012301617A1 (en) | 2011-09-02 | 2014-04-17 | Salk Institute For Biological Studies | CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity |
KR20140067092A (ko) | 2011-09-07 | 2014-06-03 | 마리나 바이오테크, 인크. | 형태적으로 제한된 단량체를 갖는 핵산 화합물의 합성 및 용도 |
US9637740B2 (en) | 2012-04-02 | 2017-05-02 | President And Fellows Of Harvard College | Cancer treatment and immune system regulation through FAT10 pathway inhibition |
EP2850092B1 (de) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclische nukleinsäureanaloga |
JP2016522674A (ja) * | 2012-05-16 | 2016-08-04 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
US9951061B2 (en) | 2013-03-06 | 2018-04-24 | Allosteros Therapeutics, Inc. | CaMKII inhibitors and uses thereof |
WO2014179492A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
JP6387084B2 (ja) | 2013-05-01 | 2018-09-05 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | アポリポタンパク質c−iiiの発現を調節するための組成物および方法 |
EP3591054A1 (de) * | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Gegen pcsk9 gerichtete antisense-oligomere und konjugate |
JP6782227B2 (ja) | 2014-09-05 | 2020-11-11 | ザ・ジョンズ・ホプキンス・ユニバーシティー | CaMKII阻害剤及びその使用 |
PT3265563T (pt) | 2015-02-02 | 2021-06-03 | Meiragtx Uk Ii Ltd | Regulação da expressão genética por modulação mediada por aptâmero de splicing alternativo |
WO2016170348A2 (en) | 2015-04-22 | 2016-10-27 | Mina Therapeutics Limited | Sarna compositions and methods of use |
WO2017011286A1 (en) * | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
EP3353305A4 (de) | 2015-09-25 | 2019-09-18 | Ionis Pharmaceuticals, Inc. | Konjugierte antisense-verbindungen und deren verwendung |
WO2017053999A1 (en) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
WO2017106283A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of liver diseases |
EP3481857A1 (de) * | 2016-07-06 | 2019-05-15 | Crispr Therapeutics AG | Materialien und verfahren zur behandlung von schmerbedingten erkrankungen |
WO2018025085A2 (en) | 2016-08-03 | 2018-02-08 | Meiragtx Uk Ii Limited | High throughput cell-based screening for aptamers |
EP3681489A4 (de) | 2017-09-10 | 2021-05-26 | Carmel Haifa University Economic Corporation Ltd. | Verfahren zur behandlung von depression und schwerer depression |
WO2019143847A1 (en) | 2018-01-18 | 2019-07-25 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
WO2019165067A1 (en) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
WO2019217459A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
-
2019
- 2019-02-21 WO PCT/US2019/018947 patent/WO2019165067A1/en unknown
- 2019-02-21 SG SG11202007652UA patent/SG11202007652UA/en unknown
- 2019-02-21 AU AU2019226001A patent/AU2019226001A1/en active Pending
- 2019-02-21 BR BR112020016347-3A patent/BR112020016347A2/pt unknown
- 2019-02-21 EP EP19710527.3A patent/EP3755800A1/de active Pending
- 2019-02-21 US US16/282,138 patent/US11058767B2/en active Active
- 2019-02-21 KR KR1020207026765A patent/KR20200140805A/ko not_active Application Discontinuation
- 2019-02-21 MX MX2020008581A patent/MX2020008581A/es unknown
- 2019-02-21 CN CN201980025466.8A patent/CN112020559A/zh active Pending
- 2019-02-21 US US16/281,138 patent/US11083444B2/en active Active
- 2019-02-21 CA CA3091789A patent/CA3091789A1/en active Pending
- 2019-02-21 JP JP2020544270A patent/JP2021513861A/ja active Pending
-
2020
- 2020-08-06 IL IL276549A patent/IL276549A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020008581A (es) | 2020-09-21 |
WO2019165067A1 (en) | 2019-08-29 |
CA3091789A1 (en) | 2019-08-29 |
US20190321022A1 (en) | 2019-10-24 |
BR112020016347A2 (pt) | 2021-01-12 |
US11058767B2 (en) | 2021-07-13 |
IL276549A (en) | 2020-09-30 |
EP3755800A1 (de) | 2020-12-30 |
AU2019226001A1 (en) | 2020-09-03 |
US11083444B2 (en) | 2021-08-10 |
CN112020559A (zh) | 2020-12-01 |
JP2021513861A (ja) | 2021-06-03 |
US20190275148A1 (en) | 2019-09-12 |
KR20200140805A (ko) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276549A (en) | CAMK2D antisense oligonucleotides and their uses | |
IL268422A (en) | Targeted oligonucleotides | |
HK1248276A1 (zh) | Tau 反義低聚物及其用途 | |
IL275950A (en) | Antisense alpha-synuclein oligonucleotides and their use | |
GB201711809D0 (en) | Antisense oligonucleotide | |
IL293377A (en) | hsd17b13 variants and their uses | |
IL269714A (en) | Oligonucleotide probes and their uses | |
GB201904709D0 (en) | Chemically modified oligonucleotides | |
IL275903A (en) | Antisense oligonucleotides directed against alpha-synculin and their uses | |
IL275902A (en) | Antisense oligonucleotides directed against alpha-synculin and their uses | |
SG10201913477UA (en) | G-quadruplex-containing antisense oligonucleotides | |
IL260193A (en) | Tlr inhibitory oligonucleotides and their use | |
EP3724206A4 (de) | Konjugierte antisense-verbindungen und deren verwendung | |
IL280581A (en) | RNAi variant against alpha-synuclein | |
SG10201609048RA (en) | Antisense oligonucleotides | |
SG10202008771WA (en) | Combination therapy with liposomal antisense oligonucleotides | |
EP4041248A4 (de) | Modifizierte oligonukleotide | |
GB201714409D0 (en) | Oligonucleotides and analogues thereof | |
IL286826A (en) | angptl2 oligonucleotides and their use | |
EP4069844A4 (de) | Anti-slc6a1-oligonukleotide und zugehörige verfahren | |
GB201704374D0 (en) | Improved metering systems and methods | |
SG11202008247WA (en) | Matrix metalloproteinase-1 antisense oligonucleotides | |
SG11202012829RA (en) | Acetyl-coa carboxylase2 antisense oligonucleotides | |
GB201714330D0 (en) | Oligonucleotides | |
EP3565825A4 (de) | Snap25-antisense-oligonukleotide |